Compare Abeona Therapeutics Inc (ABEO) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Capri Holdings Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Capri Holdings Ltd trades at $17.91 (market cap $2.23B). The key difference: Capri Holdings Ltd is far larger — about 6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | CPRI | |
|---|---|---|
Market Cap | $373.32M | $2.23B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $27.66 |
52-Week Low | $4.17 | $16.79 |
Enterprise Value | $228.22M | $3.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CPRI trades at $19.41, up 2.37% today, amid mixed signals with bearish technical indicators but improving fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $0.22 versus $0.118, while revenue trends show stabilization after declines. The company's net income margin improved to 3.94% for 2026, though 2025 saw a significant loss. Analyst consensus is mixed with 44% buy ratings and a $23.43 price target, suggesting potential upside from current levels.
The outlook hinges on CPRI's turnaround execution, with risks including luxury demand volatility and high debt. Positive catalysts include projected FY2027 growth and cost management efforts. Investors should weigh the attractive P/S ratio of 0.65 against ongoing operational challenges and insider selling noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
